COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Cannabis Science, Inc. (OTCBB: CBIS), a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is pleased to provide insight on the upcoming release of its’ new over-the-counter skin and nutraceutical product line to be branded “Phytiva” through its newest venture Phytiva Pharmaceuticals Inc. The Company is working as fast as it can to make its cannabis-based formulations that target critical ailments more widely available through multiple regulatory body guidelines. This approach will allow the Company to release its formulations to multiple markets reaching the maximum amount of people in the shortest time frame across the nation and internationally. To support this cause Cannabis Science has been working with numerous patients who have been documenting their self-medicating treatment process using the cannabis-extracts.
